Orbis Medicines与诺和诺德达成14亿美元药物合作协议

格隆汇
Yesterday
Orbis Medicines宣布与诺和诺德签署一项药物研发及授权协议,该协议潜在总价值高达14亿美元,旨在将目前需要注射给药的心脏代谢疾病治疗药物开发为口服制剂。根据协议条款,诺和诺德公司将向Orbis支付预付款及里程碑付款,并在未来产品销售中按阶梯式比例支付特许权使用费。此外,诺和诺德公司还将对这家私营企业进行战略性投资。目前,Orbis与诺和诺德公司均未披露此次战略投资的具体金额,也未透露14亿美元潜在交易总额的详细构成。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10